ROIV Roivant Sciences Ltd
Company Analysis
Latest News
🟢 Roivant Sciences is trading 4.53% up today amid a biotech-sector M&A tailwind
Roivant Sciences is trading at $35.05, up +4.53%, as biotech-sector momentum may be helping; no company-specific catalyst was identified. - No Roivant-specific...
🟢 Roivant Sciences is trading 23.22% up in after-hours trading; catalyst remains unclear
Roivant Sciences is trading at $41.32, up 23.22%, with the after-hours catalyst unclear. - No verified October 16 company-specific announcement surfaced to...
🟢 Roivant Sciences is trading 4.59% up in pre-market on October 14, 2026; catalyst remains unclear
Roivant Sciences is trading at $34.88, up 4.59%, with the catalyst for the pre-market move unclear. - No verified overnight company announcement or report...
🔴 Roivant Sciences is trading 4% down today as oil and Treasury yields stoke inflation concerns
Roivant Sciences is trading at $33.35 (-4.03%) amid broad risk-off sentiment as higher oil prices and Treasury yields raise inflation concerns. - Reuters...
🔴 Roivant Sciences is trading 5% down in pre-market
Roivant Sciences is trading down 5.06% in pre-market at $32.99 on October 8, with no clear company-specific announcement identified as the cause. - It closed...
Roivant Boosts Finances with $950 Million Moderna Patent Settlement
Roivant Sciences subsidiary Genevant Sciences and Arbutus Biopharma received a $950 million upfront payment from Moderna to settle a patent-infringement...
Roivant, Immunovant Halt Lupus Drug Development After Trial Misses Main Goal
Roivant Sciences and its majority-owned subsidiary Immunovant are discontinuing the development of their experimental drug, IMVT-1402, for treating cutaneous...
🟢 Roivant Sciences rises 4.1% — Biotech Sector Surges in Pre-Market on Multiple Positive News Snippets
With Biotech (XBI) up 2.6%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Roivant Sciences is trading 24% down today in after-hours trading with no specific negative announcement identified
Roivant Sciences is trading 23.81% lower at $29.12 after-hours on September 22, 2026, versus the regular-session close of $38.22; available coverage identifies...
🔴 Roivant Sciences is trading 24.49% down in after-hours trading amid possible after-hours liquidity or data anomaly
Roivant Sciences is trading at $30.03, down 24.49% after closing at $39.77 on September 18, 2026; the move may reflect an after-hours liquidity or data anomaly...
Roivant Sciences Rises, Stifel Sets $51 Target on Autoimmune Pipeline
Stifel initiated coverage on Roivant Sciences (ROIV) with a Buy rating and a $51.00 price target. The firm identifies a multi-asset opportunity within...
🔴 Roivant Sciences falls 4.1% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Roivant Sciences is trading 15.41% down in after-hours trading; no reliable catalyst identified
Roivant Sciences is trading 15.41% down at $34.53, with the after-hours reversal remaining unexplained. - Closed at $40.82 on September 11, 2026. - No...
Roivant Reports Positive Phase 2 Trial Data for Mosliciguat, Initiates Phase 3 Study
Roivant Sciences announced positive results from its Phase 2 PHocus clinical trial for mosliciguat in patients with pulmonary hypertension associated with...
🟢 Roivant Sciences is trading 13.46% up today after positive Phase 2 PHocus results
Roivant Sciences is trading 13.46% up now at $39.63 after positive Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with...
Roivant Surges 21% on Blockbuster Lung Drug Data — But Can a Phase 2 Win Sustain a $7 Billion Bet?
Shares of Roivant Sciences vaulted +21.2% to $42.33 this morning after the company disclosed what it called the strongest efficacy ever recorded in a...
🟢 Roivant Sciences surges 21% in pre-market on positive mosliciguat PHocus topline results
Roivant Sciences is trading at $42.33, up +21.19%, following the announcement of positive Phase 2 PHocus topline results for mosliciguat. The positive results...
Roivant Announces FDA Approval and Immediate Launch of LISRAYA™ for Dermatomyositis
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...
🔴 Roivant Sciences is trading 4.07% down today
Roivant Sciences is trading 4.07% down at $36.05 after opening-day weakness on August 28, 2026. - The FDA approval of LISRAYA for adult dermatomyositis was...
Roivant Announces FDA Approval for LISRAYA™, a New Dermatomyositis Treatment
Roivant Sciences announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) for the treatment of adults with...